NATCO completes acquisition of Dash Pharmaceuticals LLC01 January 2022
Saturday January 1, 2022 at 6:24 pm
NATCO Pharma Inc. USA, a wholly owned subsidiary of NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816) (“NATCO”), has completed the acquisition of Dash Pharmaceuticals LLC (“Dash”), a New Jersey based entity. Pursuant to this, Dash will become a 100% wholly owned subsidiary of NATCO Pharma Inc. and a step-down subsidiary of NATCO. The acquisition amount paid is US$ 18 million.
Dash is a front-end pharmaceutical sales, marketing and distribution entity in the USA which is expected to have Net Sales of approximately USD 15 million for the financial year ending December 2021.
This acquisition provides NATCO with a platform to engage with its customers directly in the USA which is the largest pharmaceutical market in the world
